{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:00:05Z","timestamp":1792501205080,"version":"4.5.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03251-4","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T14:13:25Z","timestamp":1770732805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Natural simple coumarins and their interaction with AKR1C3: implications for overcoming chemoradioresistance in gastrointestinal carcinomas"],"prefix":"10.1007","volume":"43","author":[{"given":"Zahra Nasiri","family":"Sarvi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Gholamhosseinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Iranshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh B.","family":"Rassouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"issue":"3","key":"3251_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"3251_CR2","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/cac2.70017","volume":"45","author":"M Li","year":"2025","unstructured":"Li M, Cao S, Xu R-H. Global trends and epidemiological shifts in Gastrointestinal cancers: insights from the past four decades. Cancer Commun. 2025;45(7):774\u201388. https:\/\/doi.org\/10.1002\/cac2.70017.","journal-title":"Cancer Commun"},{"issue":"1","key":"3251_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41575-023-00841-9","volume":"21","author":"CC Murphy","year":"2024","unstructured":"Murphy CC, Zaki TA. Changing epidemiology of colorectal cancer \u2014 birth cohort effects and emerging risk factors. Nat Rev Gastroenterol Hepatol. 2024;21(1):25\u201334. https:\/\/doi.org\/10.1038\/s41575-023-00841-9.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"3251_CR4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1053\/j.gastro.2023.12.022","volume":"166","author":"Y-C Chen","year":"2024","unstructured":"Chen Y-C, et al. Global prevalence of Helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022. Gastroenterol. 2024;166(4):605\u201319. https:\/\/doi.org\/10.1053\/j.gastro.2023.12.022.","journal-title":"Gastroenterol"},{"issue":"6","key":"3251_CR5","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u2013606. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.021.","journal-title":"J Hepatol"},{"issue":"3","key":"3251_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan E, et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology. 2022;163(3):649\u201358. https:\/\/doi.org\/10.1053\/j.gastro.2022.05.054.","journal-title":"Gastroenterology"},{"issue":"2","key":"3251_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","volume":"163","author":"LD Wood","year":"2022","unstructured":"Wood LD, et al. Pancreatic cancer: Pathogenesis, Screening, Diagnosis, and treatment. Gastroenterology. 2022;163(2):386\u2013402. https:\/\/doi.org\/10.1053\/j.gastro.2022.03.056.","journal-title":"Gastroenterology"},{"issue":"1","key":"3251_CR8","doi-asserted-by":"publisher","first-page":"200767","DOI":"10.1016\/j.omton.2024.200767","volume":"32","author":"A Sikora","year":"2024","unstructured":"Sikora A, et al. Emerging therapeutic approaches for peritoneal metastases from Gastrointestinal cancers. Mol Ther Oncol. 2024;32(1):200767. https:\/\/doi.org\/10.1016\/j.omton.2024.200767.","journal-title":"Mol Ther Oncol"},{"issue":"12","key":"3251_CR9","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1245\/s10434-016-5343-8","volume":"23","author":"C Meguid","year":"2016","unstructured":"Meguid C, et al. The multidisciplinary approach to GI cancer results in change of diagnosis and management of patients. multidisciplinary care impacts diagnosis and management of patients. Ann Surg Oncol. 2016;23(12):3986\u201390. https:\/\/doi.org\/10.1245\/s10434-016-5343-8.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"3251_CR10","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2023","unstructured":"Anand U, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2023;10(4):1367\u2013401. https:\/\/doi.org\/10.1016\/j.gendis.2022.02.007.","journal-title":"Genes Dis"},{"issue":"1","key":"3251_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","volume":"22","author":"SU Khan","year":"2024","unstructured":"Khan SU, et al. Unveiling the mechanisms and challenges of cancer drug resistance. Cell Commun Signal. 2024;22(1):109. https:\/\/doi.org\/10.1186\/s12964-023-01302-1.","journal-title":"Cell Commun Signal"},{"issue":"3","key":"3251_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/mco2.55","volume":"2","author":"Y-P Liu","year":"2021","unstructured":"Liu Y-P, et al. Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. MedComm. 2021;2(3):315\u201340. https:\/\/doi.org\/10.1002\/mco2.55.","journal-title":"MedComm"},{"key":"3251_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093233","volume":"21","author":"K Bukowski","year":"2020","unstructured":"Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020;21:3233. https:\/\/doi.org\/10.3390\/ijms21093233.","journal-title":"Int J Mol Sci"},{"key":"3251_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11080825","volume":"11","author":"Y Matsumoto","year":"2021","unstructured":"Matsumoto Y, et al. A critical review of radiation therapy: from particle beam therapy (Proton, Carbon, and BNCT) to beyond. J Pers Med. 2021;11:825. https:\/\/doi.org\/10.3390\/jpm11080825.","journal-title":"J Pers Med"},{"issue":"1","key":"3251_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/diseases13010022","volume":"13","author":"AA Akhunzianov","year":"2025","unstructured":"Akhunzianov AA, et al. Resistance to radiotherapy in cancer. Diseases. 2025;13(1):22. https:\/\/doi.org\/10.3390\/diseases13010022.","journal-title":"Diseases"},{"issue":"1","key":"3251_CR16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-023-01801-2","volume":"22","author":"Y Wu","year":"2023","unstructured":"Wu Y, et al. Molecular mechanisms of tumor resistance to radiotherapy. Mol Cancer. 2023;22(1):96. https:\/\/doi.org\/10.1186\/s12943-023-01801-2.","journal-title":"Mol Cancer"},{"key":"3251_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1378292","author":"M Li","year":"2024","unstructured":"Li M, et al. AKR1C3 in carcinomas: from multifaceted roles to therapeutic strategies. Front Pharmacol. 2024. https:\/\/doi.org\/10.3389\/fphar.2024.1378292.","journal-title":"Front Pharmacol"},{"issue":"3","key":"3251_CR18","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1124\/pharmrev.120.000122","volume":"73","author":"TM Penning","year":"2021","unstructured":"Penning TM, et al. Aldo-Keto reductases and cancer drug resistance. Pharmacol Rev. 2021;73(3):1150\u201371. https:\/\/doi.org\/10.1124\/pharmrev.120.000122.","journal-title":"Pharmacol Rev"},{"issue":"8","key":"3251_CR19","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1021\/acsmedchemlett.2c00175","volume":"13","author":"S He","year":"2022","unstructured":"He S, et al. Discovery of novel Aldo-Keto reductase 1C3 inhibitors as chemotherapeutic potentiators for cancer drug resistance. ACS Med Chem Lett. 2022;13(8):1286\u201394. https:\/\/doi.org\/10.1021\/acsmedchemlett.2c00175.","journal-title":"ACS Med Chem Lett"},{"issue":"2","key":"3251_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G, et al. Anthracyclines: molecular advances and Pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185\u2013229. https:\/\/doi.org\/10.1124\/pr.56.2.6.","journal-title":"Pharmacol Rev"},{"key":"3251_CR21","doi-asserted-by":"publisher","first-page":"110038","DOI":"10.1016\/j.cellsig.2021.110038","volume":"84","author":"D Pan","year":"2021","unstructured":"Pan D, et al. AKR1C3 decreased CML sensitivity to Imatinib in bone marrow microenvironment via dysregulation of miR-379-5. Cell Signal. 2021;84:110038. https:\/\/doi.org\/10.1016\/j.cellsig.2021.110038.","journal-title":"Cell Signal"},{"issue":"1","key":"3251_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.cbi.2012.09.024","volume":"202","author":"T Matsunaga","year":"2013","unstructured":"Matsunaga T, et al. Pathophysiological roles of aldo\u2013keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers. Chem -Biol Interact. 2013;202(1):234\u201342. https:\/\/doi.org\/10.1016\/j.cbi.2012.09.024.","journal-title":"Chem -Biol Interact"},{"issue":"3","key":"3251_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/jb\/mvac098","volume":"173","author":"T Matsunaga","year":"2023","unstructured":"Matsunaga T, et al. Availability of aldo-keto reductase 1C3 and ATP-binding cassette B1 as therapeutic targets for alleviating Paclitaxel resistance in breast cancer MCF7 cells. J Biochem. 2023;173(3):167\u201375. https:\/\/doi.org\/10.1093\/jb\/mvac098.","journal-title":"J Biochem"},{"issue":"2, Supplement","key":"3251_CR24","doi-asserted-by":"publisher","first-page":"e248","DOI":"10.1016\/j.ijrobp.2023.06.1187","volume":"117","author":"F Lyu","year":"2023","unstructured":"Lyu F, et al. Radiotherapy resistance in prostate cancer cells: AKR1C3 Inhibition of ubiquitinated degradation of Nrf2 through interaction with KEAP1. Int J Radiat Oncol Biol Phys. 2023;117(2, Supplement):e248. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.06.1187.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"3251_CR25","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1186\/s12885-024-13012-z","volume":"24","author":"W Xiong","year":"2024","unstructured":"Xiong W, et al. Aldo-keto reductase family 1 member C3 mediates radioresistance of esophageal cancer cells through suppressing MAPK and AKT signaling. BMC Cancer. 2024;24(1):1236. https:\/\/doi.org\/10.1186\/s12885-024-13012-z.","journal-title":"BMC Cancer"},{"issue":"1","key":"3251_CR26","doi-asserted-by":"publisher","first-page":"6492346","DOI":"10.1155\/2021\/6492346","volume":"2021","author":"J Sharifi-Rad","year":"2021","unstructured":"Sharifi-Rad J, et al. Natural coumarins: exploring the Pharmacological complexity and underlying molecular mechanisms. Oxid Med Cell Longev. 2021;2021(1):6492346. https:\/\/doi.org\/10.1155\/2021\/6492346.","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"3251_CR27","doi-asserted-by":"publisher","first-page":"11770","DOI":"10.1038\/s41598-024-62747-z","volume":"14","author":"M Shakiba","year":"2024","unstructured":"Shakiba M, Rassouli FB. Joining up the scattered anticancer knowledge on auraptene and umbelliprenin: a meta-analysis. Sci Rep. 2024;14(1):11770. https:\/\/doi.org\/10.1038\/s41598-024-62747-z.","journal-title":"Sci Rep"},{"key":"3251_CR28","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-83582018360100016","author":"MI Hussain","year":"2018","unstructured":"Hussain MI, Qamar Abbas S, Reigosa MJ. Activities and Novel Applications of Secondary Metabolite Coumarins. Planta Daninha. 2018. https:\/\/doi.org\/10.1590\/S0100-83582018360100016.","journal-title":"Planta Daninha"},{"key":"3251_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/9780470742761","volume-title":"Medicinal Natural Products: A Biosynthetic Approach","author":"PM Dewick","year":"2009","unstructured":"Dewick PM. Medicinal Natural Products: A Biosynthetic Approach. Third ed. John Wiley & Sons, Ltd.; 2009. https:\/\/doi.org\/10.1002\/9780470742761.","edition":"Third ed"},{"issue":"12","key":"3251_CR30","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3390\/ph16121732","volume":"16","author":"A Kornicka","year":"2023","unstructured":"Kornicka A, et al. Umbelliferone and its synthetic derivatives as suitable molecules for the development of agents with biological activities: A review of their Pharmacological and therapeutic potential. Pharmaceuticals. 2023;16(12):1732. https:\/\/doi.org\/10.3390\/ph16121732.","journal-title":"Pharmaceuticals"},{"issue":"4","key":"3251_CR31","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s10787-023-01256-3","volume":"31","author":"Z Lin","year":"2023","unstructured":"Lin Z, Cheng X, Zheng H. Umbelliferon: a review of its pharmacology, toxicity and pharmacokinetics. Inflammopharmacology. 2023;31(4):1731\u201350. https:\/\/doi.org\/10.1007\/s10787-023-01256-3.","journal-title":"Inflammopharmacology"},{"issue":"1","key":"3251_CR32","doi-asserted-by":"publisher","first-page":"e1948","DOI":"10.1002\/cnr2.1948","volume":"7","author":"M Rezoan Hossain","year":"2024","unstructured":"Rezoan Hossain M, et al. Esculetin unveiled: decoding its anti-tumor potential through molecular mechanisms\u2014A comprehensive review. Cancer Rep. 2024;7(1):e1948. https:\/\/doi.org\/10.1002\/cnr2.1948.","journal-title":"Cancer Rep"},{"issue":"1","key":"3251_CR33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3892\/ol.2024.14438","volume":"28","author":"M Liu","year":"2024","unstructured":"Liu M, et al. Therapeutic potential of Esculetin in various cancer types (Review). Oncol Lett. 2024;28(1):305. https:\/\/doi.org\/10.3892\/ol.2024.14438.","journal-title":"Oncol Lett"},{"issue":"1","key":"3251_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/2221-1691.367685","volume":"13","author":"L Meilawati","year":"2023","unstructured":"Meilawati L, et al. Scopoletin: anticancer potential and mechanism of action. Asian Pac J Trop Biomed. 2023;13(1):1\u20138. https:\/\/doi.org\/10.4103\/2221-1691.367685.","journal-title":"Asian Pac J Trop Biomed"},{"key":"3251_CR35","doi-asserted-by":"publisher","first-page":"105777","DOI":"10.1016\/j.biocel.2020.105777","volume":"125","author":"S Ren","year":"2020","unstructured":"Ren S, et al. Fraxetin inhibits the growth of colon adenocarcinoma cells via the Janus kinase 2\/signal transducer and activator of transcription 3 signalling pathway. Int J Biochem Cell Biol. 2020;125:105777. https:\/\/doi.org\/10.1016\/j.biocel.2020.105777.","journal-title":"Int J Biochem Cell Biol"},{"key":"3251_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13010112","volume":"13","author":"J Song","year":"2021","unstructured":"Song J, et al. Fraxetin Suppresses Cell Proliferation and Induces Apoptosis through Mitochondria Dysfunction in Human Hepatocellular Carcinoma Cell Lines Huh7 and Hep3B. Pharmaceutics. 2021;13:112. https:\/\/doi.org\/10.3390\/pharmaceutics13010112.","journal-title":"Pharmaceutics"},{"issue":"1","key":"3251_CR37","doi-asserted-by":"publisher","first-page":"e23556","DOI":"10.1002\/jbt.23556","volume":"38","author":"M Weng","year":"2024","unstructured":"Weng M, et al. Fraxetin inhibits proliferation and induces apoptosis of bladder cancer through the Akt pathway in vitro and in vivo. J Biochem Mol Toxicol. 2024;38(1):e23556. https:\/\/doi.org\/10.1002\/jbt.23556.","journal-title":"J Biochem Mol Toxicol"},{"issue":"2","key":"3251_CR38","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/ddr.21881","volume":"83","author":"H Yao","year":"2022","unstructured":"Yao H, et al. Fraxetin exerts anticancer effect in glioma by suppressing MiR-21-3. Drug Dev Res. 2022;83(2):501\u201311. https:\/\/doi.org\/10.1002\/ddr.21881.","journal-title":"Drug Dev Res"},{"issue":"9","key":"3251_CR39","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.4251\/wjgo.v13.i9.1164","volume":"13","author":"N Li","year":"2021","unstructured":"Li N, et al. Scoparone inhibits pancreatic cancer through PI3K\/Akt signaling pathway. World J Gastrointest Oncol. 2021;13(9):1164\u201383. https:\/\/doi.org\/10.4251\/wjgo.v13.i9.1164.","journal-title":"World J Gastrointest Oncol"},{"key":"3251_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2023.105627","volume":"91","author":"H Shen","year":"2023","unstructured":"Shen H, et al. Scoparone induces both apoptosis and ferroptosis via multiple mechanisms in non-small-cell lung cancer cells. Toxicol In Vitro. 2023;91:105627. https:\/\/doi.org\/10.1016\/j.tiv.2023.105627.","journal-title":"Toxicol In Vitro"},{"issue":"1","key":"3251_CR41","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3892\/etm.2023.12027","volume":"26","author":"X Wu","year":"2023","unstructured":"Wu X, et al. Scoparone inhibits breast cancer cell viability through the NF\u2013\u03baB signaling pathway. Exp Ther Med. 2023;26(1):328. https:\/\/doi.org\/10.3892\/etm.2023.12027.","journal-title":"Exp Ther Med"},{"key":"3251_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.698352","author":"Z Tayarani-Najaran","year":"2021","unstructured":"Tayarani-Najaran Z, Tayarani-Najaran N, Eghbali S. A review of auraptene as an anticancer agent. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.698352.","journal-title":"Front Pharmacol"},{"issue":"2","key":"3251_CR43","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11101-020-09713-5","volume":"21","author":"S Fiorito","year":"2022","unstructured":"Fiorito S, et al. Auraptene and umbelliprenin: a review on their latest literature acquisitions. Phytochem Rev. 2022;21(2):317\u201326. https:\/\/doi.org\/10.1007\/s11101-020-09713-5.","journal-title":"Phytochem Rev"},{"issue":"8","key":"3251_CR44","doi-asserted-by":"publisher","first-page":"10139","DOI":"10.1007\/s00210-025-03847-z","volume":"398","author":"F Hosseini","year":"2025","unstructured":"Hosseini F, et al. 7-Geranyloxycoumarin modulated metastatic potential of osteosarcoma cells via interaction with MMPs and JAK1\/2. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(8):10139\u201353. https:\/\/doi.org\/10.1007\/s00210-025-03847-z.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3251_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8050126","volume":"8","author":"I Shahzadi","year":"2020","unstructured":"Shahzadi I, et al. Assessment of the Antitumor Potential of Umbelliprenin, a Naturally Occurring Sesquiterpene Coumarin. Biomedicines. 2020;8:126. https:\/\/doi.org\/10.3390\/biomedicines8050126.","journal-title":"Biomedicines"},{"issue":"14","key":"3251_CR46","doi-asserted-by":"publisher","first-page":"15277","DOI":"10.1002\/cam4.6170","volume":"12","author":"H Wang","year":"2023","unstructured":"Wang H, et al. Umbelliprenin induces autophagy and apoptosis while inhibits cancer cell stemness in pancreatic cancer cells. Cancer Med. 2023;12(14):15277\u201388. https:\/\/doi.org\/10.1002\/cam4.6170.","journal-title":"Cancer Med"},{"issue":"2","key":"3251_CR47","doi-asserted-by":"publisher","first-page":"226","DOI":"10.30476\/mejc.2021.86492.1347","volume":"13","author":"S Mahmoodi Khatonabadi","year":"2022","unstructured":"Mahmoodi Khatonabadi S, et al. Umbelliprenin inhibited angiogenesis and metastasis of MDA-MB-231 cell line through downregulation of CoCl2 \/ EGFMediated PI3K \/ AKT \/ ERK signaling. Middle East J Cancer. 2022;13(2):226\u201336. https:\/\/doi.org\/10.30476\/mejc.2021.86492.1347.","journal-title":"Middle East J Cancer"},{"issue":"W1","key":"3251_CR48","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556\u201360. https:\/\/doi.org\/10.1093\/nar\/gkz430.","journal-title":"Nucleic Acids Res"},{"key":"3251_CR49","unstructured":"Core Team R. R: A Language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria; 2024."},{"key":"3251_CR50","unstructured":"Posit team, RStudio: Integrated Development Environment for R. 2024, Posit Software, PBC: Boston, MA."},{"issue":"7","key":"3251_CR51","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47\u2013e. https:\/\/doi.org\/10.1093\/nar\/gkv007.","journal-title":"Nucleic Acids Res"},{"issue":"14","key":"3251_CR52","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1093\/bioinformatics\/btm254","volume":"23","author":"S Davis","year":"2007","unstructured":"Davis S, Meltzer PS. GEOquery: a bridge between the gene expression omnibus (GEO) and BioConductor. Bioinformatics. 2007;23(14):1846\u20137. https:\/\/doi.org\/10.1093\/bioinformatics\/btm254.","journal-title":"Bioinformatics"},{"issue":"1","key":"3251_CR53","doi-asserted-by":"publisher","first-page":"p1301","DOI":"10.1002\/cpbi.5","volume":"54","author":"G Stelzer","year":"2016","unstructured":"Stelzer G, et al. The genecards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinform. 2016;54(1):p1301\u201313033. https:\/\/doi.org\/10.1002\/cpbi.5.","journal-title":"Curr Protoc Bioinform"},{"issue":"D1","key":"3251_CR54","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk D, et al. The STRING database in 2023: protein\u2013protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638\u201346. https:\/\/doi.org\/10.1093\/nar\/gkac1000.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"3251_CR55","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498\u2013504. https:\/\/doi.org\/10.1101\/gr.1239303.","journal-title":"Genome Res"},{"issue":"4","key":"3251_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-8-S4-S11","volume":"8","author":"C-H Chin","year":"2014","unstructured":"Chin C-H, et al. CytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(4):S11. https:\/\/doi.org\/10.1186\/1752-0509-8-S4-S11.","journal-title":"BMC Syst Biol"},{"issue":"1","key":"3251_CR57","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14(1):128. https:\/\/doi.org\/10.1186\/1471-2105-14-128.","journal-title":"BMC Bioinformatics"},{"issue":"W1","key":"3251_CR58","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1):W90\u20137. https:\/\/doi.org\/10.1093\/nar\/gkw377.","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"3251_CR59","doi-asserted-by":"publisher","first-page":"W611","DOI":"10.1093\/nar\/gkac305","volume":"50","author":"K Sch\u00f6ning-Stierand","year":"2022","unstructured":"Sch\u00f6ning-Stierand K, et al. ProteinsPlus: a comprehensive collection of web-based molecular modeling tools. Nucleic Acids Res. 2022;50(W1):W611\u20135. https:\/\/doi.org\/10.1093\/nar\/gkac305.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"3251_CR60","doi-asserted-by":"publisher","first-page":"6502","DOI":"10.1021\/acs.jcim.0c01095","volume":"60","author":"F Flachsenberg","year":"2020","unstructured":"Flachsenberg F, et al. A consistent scheme for Gradient-Based optimization of Protein\u2013Ligand poses. J Chem Inf Model. 2020;60(12):6502\u201322. https:\/\/doi.org\/10.1021\/acs.jcim.0c01095.","journal-title":"J Chem Inf Model"},{"issue":"10","key":"3251_CR61","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10822-023-00522-4","volume":"37","author":"K Diedrich","year":"2023","unstructured":"Diedrich K, et al. PoseEdit: enhanced ligand binding mode communication by interactive 2D diagrams. J Comput -Aided Mol Des. 2023;37(10):491\u2013503. https:\/\/doi.org\/10.1007\/s10822-023-00522-4.","journal-title":"J Comput -Aided Mol Des"},{"issue":"10","key":"3251_CR62","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1016\/j.bmcl.2012.03.085","volume":"22","author":"M Chen","year":"2012","unstructured":"Chen M, et al. Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer. Bioorg Med Chem Lett. 2012;22(10):3492\u20137. https:\/\/doi.org\/10.1016\/j.bmcl.2012.03.085.","journal-title":"Bioorg Med Chem Lett"},{"issue":"9","key":"3251_CR63","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1093\/bioinformatics\/btaa018","volume":"36","author":"JL Vel\u00e1zquez-Libera","year":"2020","unstructured":"Vel\u00e1zquez-Libera JL, et al. LigRMSD: a web server for automatic structure matching and RMSD calculations among identical and similar compounds in protein-ligand docking. Bioinformatics. 2020;36(9):2912\u20134. https:\/\/doi.org\/10.1093\/bioinformatics\/btaa018.","journal-title":"Bioinformatics"},{"issue":"18","key":"3251_CR64","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","volume":"32","author":"GY Di Veroli","year":"2016","unstructured":"Di Veroli GY, et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics. 2016;32(18):2866\u20138. https:\/\/doi.org\/10.1093\/bioinformatics\/btw230.","journal-title":"Bioinformatics"},{"issue":"1","key":"3251_CR65","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1186\/s12885-021-09040-8","volume":"21","author":"D Xu","year":"2021","unstructured":"Xu D, Zhang Y, Jin F. The role of AKR1 family in Tamoxifen resistant invasive lobular breast cancer based on data mining. BMC Cancer. 2021;21(1):1321. https:\/\/doi.org\/10.1186\/s12885-021-09040-8.","journal-title":"BMC Cancer"},{"issue":"22","key":"3251_CR66","doi-asserted-by":"publisher","first-page":"12512","DOI":"10.3390\/ijms222212512","volume":"22","author":"NL Phoo","year":"2021","unstructured":"Phoo NL, et al. Transcriptomic profiling reveals AKR1C1 and AKR1C3 mediate cisplatin resistance in signet ring cell gastric carcinoma via autophagic cell death. Int J Mol Sci. 2021;22(22):12512. https:\/\/doi.org\/10.3390\/ijms222212512.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"3251_CR67","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.3390\/cancers13102403","volume":"13","author":"C Zhou","year":"2021","unstructured":"Zhou C, et al. Aldo-Keto reductase 1C3 mediates chemotherapy resistance in esophageal adenocarcinoma via ROS detoxification. Cancers. 2021;13(10):2403. https:\/\/doi.org\/10.3390\/cancers13102403.","journal-title":"Cancers"},{"issue":"1","key":"3251_CR68","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41419-025-07773-z","volume":"16","author":"F Ju","year":"2025","unstructured":"Ju F, et al. AKR1C3 enhances radioresistance in esophageal adenocarcinoma via inhibiting ferroptosis through suppressing TRIM21-mediated ubiquitination of HSPA5. Cell Death Dis. 2025;16(1):483. https:\/\/doi.org\/10.1038\/s41419-025-07773-z.","journal-title":"Cell Death Dis"},{"key":"3251_CR69","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bcp.2018.08.001","volume":"156","author":"E Novotn\u00e1","year":"2018","unstructured":"Novotn\u00e1 E, et al. Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment. Biochem Pharmacol. 2018;156:22\u201331. https:\/\/doi.org\/10.1016\/j.bcp.2018.08.001.","journal-title":"Biochem Pharmacol"},{"key":"3251_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113127","volume":"12","author":"TS Tavares","year":"2020","unstructured":"Tavares TS, et al. Olaparib synergizes the anticancer activity of daunorubicin via interaction with AKR1C3. Cancers. 2020;12:3127. https:\/\/doi.org\/10.3390\/cancers12113127.","journal-title":"Cancers"},{"issue":"9","key":"3251_CR71","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1158\/1535-7163.MCT-17-1023","volume":"17","author":"K Verma","year":"2018","unstructured":"Verma K, et al. AKR1C3 inhibitor KV-37 exhibits antineoplastic effects and potentiates enzalutamide in combination therapy in prostate adenocarcinoma cells. Mol Cancer Ther. 2018;17(9):1833\u201345. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-1023.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"3251_CR72","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1021\/acs.jmedchem.9b00090","volume":"62","author":"K Verma","year":"2019","unstructured":"Verma K, et al. Potent and highly selective Aldo\u2013Keto reductase 1C3 (AKR1C3) inhibitors act as chemotherapeutic potentiators in acute myeloid leukemia and T-Cell acute lymphoblastic leukemia. J Med Chem. 2019;62(7):3590\u2013616. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00090.","journal-title":"J Med Chem"},{"issue":"5","key":"3251_CR73","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s10637-014-0101-x","volume":"32","author":"Y Loriot","year":"2014","unstructured":"Loriot Y, et al. Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I\/II study. Investig. New Drugs. 2014;32(5):995\u20131004. https:\/\/doi.org\/10.1007\/s10637-014-0101-x.","journal-title":"New Drugs"},{"key":"3251_CR74","doi-asserted-by":"publisher","first-page":"104446","DOI":"10.1016\/j.phrs.2019.104446","volume":"152","author":"TL Ri\u017ener","year":"2020","unstructured":"Ri\u017ener TL, Penning TM. Aldo-keto reductase 1C3\u2014Assessment as a new target for the treatment of endometriosis. Pharmacol Res. 2020;152:104446. https:\/\/doi.org\/10.1016\/j.phrs.2019.104446.","journal-title":"Pharmacol Res"},{"key":"3251_CR75","doi-asserted-by":"publisher","DOI":"10.29219\/fnr.v67.9024","author":"X Yu","year":"2023","unstructured":"Yu X, et al. Inhibition of castration-resistant prostate cancer growth by genistein through suppression of AKR1C3. Food Nutr Res. 2023. https:\/\/doi.org\/10.29219\/fnr.v67.9024.","journal-title":"Food Nutr Res"},{"issue":"1","key":"3251_CR76","doi-asserted-by":"publisher","first-page":"4025459","DOI":"10.1155\/jfq\/4025459","volume":"2025","author":"A Debnath","year":"2025","unstructured":"Debnath A, et al. Quercetin, Isoquercitrin, and Quercetin-3-Rutinoside: Understanding the Pharmacological, Organoleptic, ADME Properties, human health Toxicity, ecological risk, and cosmetic risk of using integrative bioinformatics. J Food Qual. 2025;2025(1):4025459. https:\/\/doi.org\/10.1155\/jfq\/4025459.","journal-title":"J Food Qual"},{"issue":"2","key":"3251_CR77","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/metabo12020099","volume":"12","author":"G M\u00f6ller","year":"2022","unstructured":"M\u00f6ller G, et al. Analogues of natural Chalcones as efficient inhibitors of AKR1C3. Metabolites. 2022;12(2):99. https:\/\/doi.org\/10.3390\/metabo12020099.","journal-title":"Metabolites"},{"key":"3251_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/scipharm91020019","volume":"91","author":"M Taboada-Alquerque","year":"2023","unstructured":"Taboada-Alquerque M, et al. Mapping protein targets of carnosol, a molecule identified in Rosmarinus officinalis: in silico docking studies and network pharmacology. Sci Pharm. 2023;91:19. https:\/\/doi.org\/10.3390\/scipharm91020019.","journal-title":"Sci Pharm"},{"issue":"9","key":"3251_CR79","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.3390\/molecules28093889","volume":"28","author":"P Wr\u00f3blewska-\u0141uczka","year":"2023","unstructured":"Wr\u00f3blewska-\u0141uczka P, G\u00f3ralczyk A, \u0141uszczki JJ. Synergy, additivity and antagonism between Esculetin and six commonly used chemotherapeutics in various malignant melanoma cell Lines\u2014An isobolographic analysis. Molecules. 2023;28(9):3889. https:\/\/doi.org\/10.3390\/molecules28093889.","journal-title":"Molecules"},{"issue":"1","key":"3251_CR80","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3329\/bjp.v10i1.21202","volume":"10","author":"MA Asgar","year":"2015","unstructured":"Asgar MA, et al. Scopoletin potentiates the anti-cancer effects of cisplatin against cholangiocarcinoma cell lines. Bangladesh J Pharmacol. 2015;10(1):69\u201377. https:\/\/doi.org\/10.3329\/bjp.v10i1.21202.","journal-title":"Bangladesh J Pharmacol"},{"issue":"2","key":"3251_CR81","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2174\/1874467208666161128152518","volume":"11","author":"C Puech","year":"2018","unstructured":"Puech C, et al. Umbelliferone decreases intracellular pH and sensitizes melanoma cell line A375 to Dacarbazin. Comparison with Acetazolamide. Curr Mol Pharmacol. 2018;11(2):133\u20139. https:\/\/doi.org\/10.2174\/1874467208666161128152518.","journal-title":"Curr Mol Pharmacol"},{"key":"3251_CR82","doi-asserted-by":"publisher","DOI":"10.1177\/1934578X211072334","author":"Z Delbari","year":"2022","unstructured":"Delbari Z, et al. Combination of umbelliprenin and arsenic trioxide acts as an effective modality against T-cell leukemia\/lymphoma cells. Nat Prod Commun. 2022. https:\/\/doi.org\/10.1177\/1934578X211072334.","journal-title":"Nat Prod Commun"},{"key":"3251_CR83","doi-asserted-by":"publisher","DOI":"10.1177\/03946320241287873","author":"K Ebrahimi","year":"2024","unstructured":"Ebrahimi K, et al. Umbelliprenin improved anti-proliferative effects of ionizing radiation on adult T-cell leukemia\/lymphoma cells via interaction with CDK6; an in vitro and in silico study. Int J Immunopathol Pharmacol. 2024. https:\/\/doi.org\/10.1177\/03946320241287873.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"8","key":"3251_CR84","doi-asserted-by":"publisher","first-page":"e43965","DOI":"10.1371\/journal.pone.0043965","volume":"7","author":"JU Flanagan","year":"2012","unstructured":"Flanagan JU, et al. Crystal structures of three classes of Non-Steroidal Anti-Inflammatory drugs in complex with Aldo-Keto reductase 1C3. PLoS ONE. 2012;7(8):e43965. https:\/\/doi.org\/10.1371\/journal.pone.0043965.","journal-title":"PLoS ONE"},{"issue":"4","key":"3251_CR85","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1107\/s1399004715002175","volume":"71","author":"Y Amano","year":"2015","unstructured":"Amano Y, et al. Structures of complexes of type 5 17[beta]-hydroxysteroid dehydrogenase with structurally diverse inhibitors: insights into the conformational changes upon inhibitor binding. Acta Crystallogr D. 2015;71(4):918\u201327. https:\/\/doi.org\/10.1107\/s1399004715002175.","journal-title":"Acta Crystallogr D"},{"issue":"7","key":"3251_CR86","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/pros.24118","volume":"81","author":"LS Graham","year":"2021","unstructured":"Graham LS, et al. Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. Prostate. 2021;81(7):418\u201326. https:\/\/doi.org\/10.1002\/pros.24118.","journal-title":"Prostate"},{"issue":"6","key":"3251_CR87","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1021\/jm3017656","volume":"56","author":"AJ Liedtke","year":"2013","unstructured":"Liedtke AJ, et al. Development of potent and selective indomethacin analogues for the Inhibition of AKR1C3 (Type 5 17\u03b2-Hydroxysteroid Dehydrogenase\/Prostaglandin F Synthase) in Castrate-Resistant prostate cancer. J Med Chem. 2013;56(6):2429\u201346. https:\/\/doi.org\/10.1021\/jm3017656.","journal-title":"J Med Chem"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03251-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03251-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03251-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T12:04:18Z","timestamp":1775649858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03251-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":87,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["3251"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03251-4","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}